Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

May 15, 2007 (Vol. 27, No. 10)

Improving Yields in Oligo Manufacturing

Growing Diversity of DNA and RNA Therapeutics Are Changing the Game

  • The therapeutic oligo landscape has certainly become more diverse in recent years. siRNA, siDNA, aptamers, immunostimulatory sequences, and miRNAs have joined the ranks of antisense oligos in developmental pipelines. Thus, defining synthesis, improving purity, and reducing manufacturing costs are growing concerns. ProNAi Therapeutics (www.pronai.com) recently reported positive preclinical ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.